-The Hindu The Supreme Court order rejecting a plea to grant patent protection for Glivec, a cancer-fighting drug from Novartis, is a landmark. It will greatly strengthen the quest for access to affordable medicines in India. The decision affirms the idea that a patent regime loses its social relevance when a drug is priced beyond the reach of the vast majority of a country's people. That pharmaceutical companies employ high pricing...
More »SEARCH RESULT
SC verdict on Novartis AG plea today
-Reuters Global drugmakers, battered by recent intellectual property decisions in the country, are girding for a landmark court ruling on Monday with broad consequences for their ability to sell lucrative patented medicines in the country. Supreme Court is due to decide on April 1 whether or not Swiss giant Novartis AG's cancer treatment Glivec deserves a patent in the country. "Big Pharma is nervous because nothing has gone in their favour in the...
More »Natco Pharma wins cancer drug case-R Sivaraman
-The Hindu Bayer's plea dismissed by the Intellectual Property Appellate Board The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs. Disposing an appeal filed by Bayer...
More »Pharma MNCs use RTI law to protect market for patented drugs & delay entry of generics
-The Economic Times Pharmaceutical multinationals have begun using the Right to Information law to launch pre-emptive legal action against local generic players to protect the market of patented drugs and delay the entry of low cost generic medicines in the 60,000-crore domestic drug market. MNCs are using such information to sue generic firms even at a stage when their marketing approval is still pending or during the few months' window between the...
More »What was thought to be milder malaria may not be so: Study-Pritha Chatterjee
-The Indian Express Ganga Ram docs link ‘benign’ parasite with platelet drop, liver problems. A malaria parasite responsible for the milder form of the disease — Plasmodium vivax — has been linked with severe complications in patients. A new study by Sir Ganga Ram Hospital doctors on 165 patients, published in the journal Tropical Doctor, says the parasite may be deadlier than thought. Of 121 patients diagnosed with vivax malaria, three died of...
More »